Pictured above: BIOE Chair John Fisher and BIOE Assoc. Chairs Yu Chen & Ian White; BIOE Advisory Board Members: Len Pinchuk, Woodie Kessel, Tim Fischell, Reg Seeto, Minh-Quan Pham, Ivor Knight (Advisory Board Chair), Susanna Naggie, Tom Borgoyn, Matthew Dowling, Jason Brooke
M. Jason Brooke
CEO & General Counsel
Vasoptic Medical Inc.
About M. Jason Brooke
Founder & CEO
Remedium Technologies, Inc. (RTI)
About Dr. Dowling
Professor, Michigan State University
Borgess Health Alliance
About Dr. Fischell
Ret. Assistant Surgeon General
Sr. Scientific Advisor, Academic Network LLC
About Dr. Kessel
Ivor T. Knight
Advisory Board Chair
Senior Vice President and Chief Technology Officer
Canon BioMedical, Inc.
Canon U.S. Life Sciences, Inc.
About Dr. Knight
Partner and Managing Director
The Boston Consulting Group
About Claudio Knizek
Antonios G. Mikos
Elected Member, National Academy of Engineering
Louis Calder Professor
Department of Bioengineering
Director, J.W. Cox Laboratory for Biomedical Engineering
Director, Center for Excellence in Tissue Engineering
BioScience Research Collaborative
About Dr. Mikos
Associate Professor of Medicine
Duke School of Medicine
About Dr. Naggie
Berenato & White
About Dr. Pham
Leonard (Len) Pinchuk
Elected Member, National Academy of Engineering
Co-Founder, President, and CEO, Innovia LLC
About Dr. Pinchuk
Reginald Seeto, M.D.
Head of Partnering Strategy
About Dr. Seeto
Michael (Mike) Shuler
Elected Member, National Academy of Engineering
James M. & Marsha McCormick Chair of Biomedical Engineering
Samuel B. Eckert Professor of Chemical Engineering
About Dr. Shuler
Senior Vice President and General Manager
About Dr. Soltani
Mr. Tom Borgoyn has worked in various roles in product development spanning a career over 35 years. These roles have included designing electronics, developing software, leading product development core teams and managing an engineering department. Borgoyn started his career working in the defense industry, designing and testing equipment for radar jamming pods and transitioned to working the majority of time in the medical diagnostics field. Throughout his tenure in the medical field, he has developed or led the development of instruments and systems for the detection of bacteria growth in normally sterile body fluids, rapid immunological tests for the flu, diagnostics tests to determine organism identification and antimicrobial susceptibility and rapid molecular PCR tests for selective bacterial infections. He is currently leading a group that is developing the next generation of automation and informatics solutions for medical diagnostics related to microbiology and molecular biology. The technologies they employ range from robotics and sample handling/preparation to data analytics in the cloud. Borgoyn initially earned a bachelor’s degree from the University of Maryland in electrical engineering and subsequently went on to acquire master’s degrees in both computer science and engineering science.
M. Jason Brooke is the Chief Executive Officer and General Counsel for Vasoptic Medical Inc., an early stage medical device company developing a mobile health solution for early detection of diabetic retinopathy. Mr. Brooke has more than 10 years of experience in design, development, and commercialization of medical device and mobile health technology. Prior to joining Vasoptic Medical, Mr. Brooke was an Associate at Epstein Becker & Green P.C. where he advised medical device companies on legal and regulatory issues throughout the product life cycle—from research and development, and pre-market clearance/approval, to post-market compliance. In addition, he acted as co-counsel to the mHealth Regulatory Coalition and the CDS Coalition, developing policy recommendations on the regulation of mobile health technology and clinical decision support software. Prior to joining Epstein Becker Green, Mr. Brooke was a Program Analyst for the FDA's Center for Devices and Radiological Health, where he reviewed proposed and final rules and guidance documents for regulatory compliance. Mr. Brooke also has considerable scientific research experience, including serving as a Senior Research Scientist at Boston Scientific Corporation (formerly Guidant Corporation), where, among other things, he planned, developed, coordinated, and analyzed results from U.S. and foreign clinical trials to develop automaticity algorithms for implantable cardiac and neural stimulation devices. Mr. Brooke received a Bachelor of Science degree in Biological Resources Engineering from the University of Maryland, a Master of Science in Engineering degree at the Biomedical Engineering Department of the Johns Hopkins University, and a Juris Doctor from the University of Maryland School of Law, where he obtained a Health Law Certificate and was the Editor-in‐Chief of the Journal of Health Care Law & Policy.
Dr. Matthew Dowling is Founder & Chief Executive Officer of Remedium Technologies, Inc. (RTI). Matt completed his graduate work at the Fischell Department of Bioengineering at the University of Maryland in May 2010 and has since pursued RTI on a full-time basis. In 2005, he was awarded the Fischell Fellowship in Biomedical Engineering for his innovative ideas in drug delivery systems, after graduating from the University of Notre Dame in Chemical Engineering. At UMD, Dr. Dowling co-created the HemogripTM wound treatment platform and raised initial seed R&D funding grants to develop the technology. Dr. Dowling was the (2010) winner of the Dean’s Doctoral Research Award from the Clark School of Engineering, the highest honor for an Engineering Doctoral student, for his work on chitosan-based self-assembled soft materials for use in wound treatment. He has since successfully licensed HemogripTM from UMD and has raised +$2.0M in non-dilutive R&D grant funding. This funding has led to five issued and seven pending patents around the technology, as well as a 510k FDA Clearance for the company’s lead product, the HemogripTM Patch, a hemostatic bandage for rapid treatment of bleeding at vascular access sites. Matt’s work was recently featured on the BBC TV program “Brave New World with Stephen Hawking.”
Dr. Fischell is Professor of Medicine at Michigan State University and Medical Director of the Department of Cardiovascular Research. He also serves as Director of the Interventional Cardiology Fellowship Program at the Borgess Heart Institute in Kalamazoo, Michigan, and where he also has an active practice as an interventional cardiologist. After receiving his medical degree from Cornell University Medical Center in New York City, Dr. Fischell completed an internship and residency in internal medicine at Massachusetts General Hospital/Harvard University in Boston, before completing his interventional cardiology fellowship at Stanford University Medical Center in Palo Alto, California. Dr. Fischell was on the faculty at Stanford for five years, and then served as Director of the cardiac cath labs and interventional cardiology at Vanderbilt University from 1992-1996. Dr. Fischell is board certified in internal medicine, cardiovascular medicine and interventional cardiology. He has served as principal investigator for three National Institutes of Health grants, as well as several other research grants, and has research interests in vascular biology, interventional cardiology devices such as stents and renal denervation. A member of the editorial board of Cardiovascular Revascularization Medicine, Journal of Invasive Cardiology, and the Journal of Interventional Cardiology, Dr. Fischell has authored more than 120 publications in peer-reviewed journals and more than 27 book chapters. Dr. Fischell is the inventor or co-inventor of more than 80 patented medical devices and is the founder or co-founder of ~10 medical device companies. He currently serves as founder and CEO of Ablative Solutions, Inc., a leading renal denervation company. He has received numerous awards and honors, including the Thorax Center Andreas Gruntzig Award for Inventor of the Year in 1997 and the CRT 2015 Innovation Award. He has had a longstanding interest in health and fitness and the effects on heart disease. Most recently he has authored the health and fitness book “Burn Calories While You Sleep; Change Your Metabolism to be Thin, Fit, healthy and live Longer,” with forward by Dr. Dean Ornish.
Dr. Woodie Kessel is a community pediatrician and child advocate with experience in bioengineering, medicine, public health, community-based programming, and public policy. Dr. Kessel is currently the Senior Child Health Scholar in Residence at the C E Koop Institute, Dartmouth College and Medical School; Professor of Pediatrics, Geisel School of Medicine, Dartmouth College; and, Professor of the Practice at the University of Maryland’s School of Public Health. He serves as a senior advisor to such organizations as PBS KIDS, Sesame Workshop, Myotonic Dystrophy Foundation, Avielle Foundation and several medical public health boards and. Previously, Dr. Kessel served in the US Public Health Service as an Assistant Surgeon General and senior advisor on child and family health matters to the White House, Cabinet Secretaries, Surgeons General, and Health and Human Services officials spanning eight administrations. Dr. Kessel’s contributions to national child health policy include the original drafting of the Children’s Health Insurance Program and the Bright Futures Guidelines for health supervision of children and adolescents. Dr. Kessel studied electrical engineering at Drexel University and worked on biotelemetry systems; medicine at the Albert Einstein College of Medicine; and, public health at the Johns Hopkins University. He completed his pediatric residency and primary care fellowship at Boston City Hospital. He was a RWJF Clinical Scholar and an ambulatory pediatrics fellow at the George Washington University’s Children’s Hospital National Medical Center.
Dr. Knight has been with Canon for 12 years, first with Canon U.S. Life Sciences and now with Canon BioMedical, and currently oversees the R&D functions of both companies. During his career at Canon he established Canon’s biomedical research and development organization and facility in Rockville, Maryland, and led the development of the first products brought to market. Prior to joining Canon, Dr. Knight was a professor at James Madison University, where he taught and conducted research in molecular genetics and microbiology. He has published widely in his field and is an inventor on numerous patents in the area of diagnostic instrumentation and chemistry. He holds a Ph.D. from the University of Maryland and is a Fellow of the American Association for the Advancement of Science.
Claudio Knizek joined The Boston Consulting Group in January 2006 and is a Partner and Managing Director in BCG's Washington D.C. office. Throughout his tenure at BCG, he has focused on a variety of operational and strategic issues affecting the Industrial and Consumer Goods sectors. The majority of Claudio's work at BCG has been focused on operational topics, particularly manufacturing and supply chain. Claudio currently co-leads BCG's Manufacturing Topic globally. Prior to joining BCG, Claudio worked at A. T. Kearney for five years. Claudio has a B.S. and M.S. from Stanford University and an M.B.A. from Harvard Business School.
Dr. Antonios G. Mikos is the Louis Calder Professor of Bioengineering and Chemical and Biomolecular Engineering at Rice University. His research focuses on the synthesis, processing, and evaluation of new biomaterials for use as scaffolds for tissue engineering, as carriers for controlled drug delivery, and as non-viral vectors for gene therapy. He is the author of over 550 publications and 28 patents. He is a Member of the National Academy of Engineering, a Member of the National Academy of Medicine, and a Member of the Academy of Athens. He is a Founding Fellow of the Tissue Engineering and Regenerative Medicine International Society, a Fellow of the American Association for the Advancement of Science, a Fellow of the American Institute of Chemical Engineers, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Biomedical Engineering Society, a Fellow of the Controlled Release Society, a Fellow of the International Union of Societies for Biomaterials Science and Engineering, and a Fellow of the National Academy of Inventors.
Dr. Susanna Naggie completed her undergraduate degrees in Chemical Engineering and Biochemistry at the University of Maryland, College Park and her medical education at Johns Hopkins School of Medicine. She completed her internal medicine and infectious diseases fellowship training at Duke University Medical Center. She joined the faculty in the Duke School of Medicine in 2009. She is an Associate Professor of Medicine and currently holds appointments at DUMC (Director, Department of Medicine Clinical Research Unit), at the Duke Clinical Research Institute (Director of ID Research), and at the Durham Veterans Affairs Medical Center. Dr. Naggie is a clinical investigator with a focus in clinical trials and translational science in HIV and HCV. Dr. Naggie is a co-Chair of the AASLD/IDSA HCV Guidance Committee, and a member of the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee and the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.
Dr. Minh-Quan K. Pham is a patent attorney with over ten years of experience in protecting innovations and providing creative legal solutions through a unique combination of perspectives, including as an inventor, a scientist/engineer, an entrepreneur, an examiner, and an attorney. Dr. Pham is experienced in all aspects of intellectual property protection, including counseling, prosecution, litigation, licensing, and portfolio management. He has represented authors, artists, educators, engineers, physicians, scientists, as well as universities, small companies, and international corporations. Prior to his legal practice, Dr. Pham was a patent examiner in group 1600, examining biotechnology patent applications. He was also a founder of Chesapeake PERL, a recombinant protein production company. Dr. Pham received his B.S. and Ph.D. in Chemical Engineering from the University of Maryland, and his J.D. from the Georgetown University Law Center.
Dr. Leonard Pinchuk is a serial inventor and entrepreneur with 115 issued U.S. patents, 80 publications and 10 companies that he co-founded. His major accomplishments include the invention of the modern-day angioplasty balloon, the helical wire stent, the modular stent-graft, a drug-eluting stent (TAXUS®), several biomaterials, a novel glaucoma shunt and the next generation intraocular lens material. He received a B.Sc. in chemistry from McGill University (1976), a Ph.D. interdisciplinary in Engineering and Chemistry from the University of Miami (1984) and an honorary Doctor of Science degree from McGill University (2005). He was inducted into AIMBE in 2007 and the National Academy of Engineering in 2012. Dr. Pinchuk began his career in 1983 at Cordis Corporation and left in 1987 to co-found Corvita Corporation (angioplasty catheters, stents, stent-grafts), which went public in 1994, was acquired by Pfizer, Inc. (1996) and then sold to Boston Scientific (1998). Dr. Pinchuk founded Innovia LLC (2002), which incubated and spun off eight new companies working in the fields of intraocular lenses, glaucoma shunts, other catheters and biomaterials. His current company, InnFocus, Inc., which has developed a novel treatment for glaucoma, was acquired by Santen Corporation in May 2016, where he will be serving as CSO for the next three years. Dr. Pinchuk also enjoys an appointment as Research Professor of Biomedical Engineering at the University of Miami.
Dr. Seeto joined the MedImmune team in 2008, and has held a number of leadership positions with the company during his tenure. In 2013, he assumed his current role on MedImmune’s executive team, in which he formed, and now leads, the company’s Partnering and Strategy Department. This group is responsible for devising and executing MedImmune’s external partnership strategy, including business development activities – from M&A and licensing to co-development, joint ventures and out-licensing - along with academic, government and non-profit collaborations and alliances to support all of MedImmune’s biologics and therapy area strategies. Seeto originally joined MedImmune as Vice President of Global Strategic Marketing and Portfolio Management where he worked closely with the R&D leadership team. He was later promoted to MedImmune’s executive team, as EVP of the Corporate Development and Strategy Group, which included the following departments: business development, corporate strategy, corporate projects, MedImmune Ventures and portfolio management. From 2011 to 2012, Seeto was on an expatriate assignment as the President of AstraZeneca Thailand, where he was the first MedImmune executive to participate in a talent exchange and development program with AstraZeneca. Under his leadership, Thailand achieved its sales targets for the first time in five years and was awarded the RVP Award for Leadership for management of the country’s worst floods in more than half a century. Prior to MedImmune, Seeto was Vice President of Global Marketing for Schering Plough/Organon Biosciences and Executive Director of US Marketing for Boehringer Ingelheim Pharmaceuticals. Earlier in his career he was a consultant at McKinsey & Company and started his career as a medical doctor involved in both clinical practice and research. He has also published first author publications in peer reviewed journals. Seeto is a Board member for BioHealth Innovation (BHI) and Definiens. He holds his medical degree (with honors) from the University of Sydney, Australia.
Dr. Michael L. Shuler is the Eckert Professor of Engineering in the Meing Department of Biomedical Engineering and in the School of Chemical and Biomolecular Engineering at Cornell University, and director of Cornell’s Nanobiotechnology Center. Shuler has degrees in chemical engineering (B.S., Notre Dame, 1969 and Ph.D., Minnesota, 1973) and has been a faculty member at Cornell University since 1974. Shuler’s research includes development of “Body-on-a-Chip” for testing pharmaceuticals for toxicity and efficacy, creation of production systems for useful compounds, such as paclitaxel from plant cell cultures, and construction of whole cell models relating genome to physiology. Shuler is CEO and President of Hesperos, a company founded to implement the “Body-on-a-Chip” system. Shuler has been elected to the National Academy of Engineering and the American Academy of Arts and Science.
Dr. Peter Soltani is a native of greater Washington, D.C. and has been involved in the medical device and diagnostics space for nearly 20 years. Peter’s early career involved technology innovation involving semiconductor and optical materials for energy conversion and imaging. He joined Hologic, Inc., a women’s health focus medical device and diagnostics company, in 2000 to lead their digital x-ray capture technology development, and eventually lead its global Women’s Health business segment. Notable accomplishment included helping develop Hologic’s digital mammography platform, now the leading product of its kind, the development and commercialization of the first 3D digital mammography system for early cancer detection, as well as innovations in tumor biopsy, tumor characterization, and surgical devices. Peter joined Siemens Medical Solutions in 2014 to lead its North American Healthcare Services business, helping develop solutions to meet the changing and complex needs of the healthcare delivery market. Peter joined Beckman-Coulter Diagnostics (a Danaher company) in January 2016 as Senior Vice President and General Manager, and leads its Hematology and Urine Analysis businesses based out of Miami, FL. Peter is a Maryland alumni, holding a BS in Chemistry (’83) and Ph.D. in Materials Science & Engineering (’94).